Is ALLO or MOLN more profitable?

Allogene Therapeutics' return on equity of -50.04% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -50.04% -36.74% Molecular Partners N/A -68.36% -54.82%

Which has preferable earnings and valuation, TECX or MOLN?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A Molecular Partners N/A N/A -$74.41M -$1.71 N/A

Is TECX or MOLN more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -35.26% -33.59% Molecular Partners N/A -68.36% -54.82%

Is MOLN or SGMT more profitable?

Sagimet Biosciences' return on equity of -31.96% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -68.36% -54.82% Sagimet Biosciences N/A -31.96% -30.57%

Is MOLN or CBIO more profitable?

Molecular Partners' return on equity of -68.36% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -68.36% -54.82% Crescent Biopharma N/A -101.50% -86.86%

Molecular Partners (MOLN) Competitors

$4.30 +0.23 (+5.60%)

As of 02:14 PM Eastern

Compare

MOLN vs. IRWD, ALLO, TECX, SGMT, and CBIO

Should you buy Molecular Partners stock or one of its competitors? Molecular Partners's main competitors and comparable companies include Ironwood Pharmaceuticals (IRWD), Allogene Therapeutics (ALLO), Tectonic Therapeutic (TECX), Sagimet Biosciences (SGMT), and Crescent Biopharma (CBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Molecular Partners compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Molecular Partners' net margin of 0.00%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Molecular Partners	N/A	-68.36%	-54.82%

Ironwood Pharmaceuticals has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.41	$24.02M	$0.77	5.62
Molecular Partners	N/A	N/A	-$74.41M	-$1.71	N/A

Ironwood Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Ironwood Pharmaceuticals currently has a consensus price target of $6.23, indicating a potential upside of 44.12%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 96.37%. Given Molecular Partners' higher probable upside, analysts clearly believe Molecular Partners is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

26.5% of Molecular Partners shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Ironwood Pharmaceuticals had 8 more articles in the media than Molecular Partners. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 0 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.15 beat Ironwood Pharmaceuticals' score of 0.36 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Ironwood Pharmaceuticals	Neutral
Molecular Partners	Positive

Summary

Ironwood Pharmaceuticals beats Molecular Partners on 11 of the 15 factors compared between the two stocks.

How does Molecular Partners compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Molecular Partners has lower revenue, but higher earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	34,117.14	-$190.89M	-$0.67	N/A
Molecular Partners	N/A	N/A	-$74.41M	-$1.71	N/A

Allogene Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Allogene Therapeutics' return on equity of -50.04% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Molecular Partners	N/A	-68.36%	-54.82%

Allogene Therapeutics currently has a consensus target price of $8.30, suggesting a potential upside of 320.25%. Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 96.37%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Allogene Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Allogene Therapeutics had 10 more articles in the media than Molecular Partners. MarketBeat recorded 10 mentions for Allogene Therapeutics and 0 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.15 beat Allogene Therapeutics' score of 0.72 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Allogene Therapeutics	Positive
Molecular Partners	Positive

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 26.5% of Molecular Partners shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Allogene Therapeutics beats Molecular Partners on 11 of the 15 factors compared between the two stocks.

How does Molecular Partners compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Molecular Partners	N/A	N/A	-$74.41M	-$1.71	N/A

Tectonic Therapeutic's return on equity of -35.26% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Molecular Partners	N/A	-68.36%	-54.82%

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 26.5% of Molecular Partners shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Tectonic Therapeutic had 8 more articles in the media than Molecular Partners. MarketBeat recorded 8 mentions for Tectonic Therapeutic and 0 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.15 beat Tectonic Therapeutic's score of 1.05 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Tectonic Therapeutic	Positive
Molecular Partners	Positive

Tectonic Therapeutic has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Tectonic Therapeutic presently has a consensus target price of $77.25, indicating a potential upside of 160.58%. Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 96.37%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, research analysts clearly believe Tectonic Therapeutic is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Tectonic Therapeutic beats Molecular Partners on 11 of the 14 factors compared between the two stocks.

How does Molecular Partners compare to Sagimet Biosciences?

Molecular Partners (NASDAQ:MOLN) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Sagimet Biosciences' return on equity of -31.96% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-68.36%	-54.82%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Molecular Partners has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.45, indicating that its share price is 245% more volatile than the broader market.

26.5% of Molecular Partners shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sagimet Biosciences has higher revenue and earnings than Molecular Partners. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	N/A	N/A	-$74.41M	-$1.71	N/A
Sagimet Biosciences	$2M	338.46	-$51.04M	-$1.28	N/A

In the previous week, Sagimet Biosciences had 5 more articles in the media than Molecular Partners. MarketBeat recorded 5 mentions for Sagimet Biosciences and 0 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.15 beat Sagimet Biosciences' score of 0.32 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Molecular Partners	Positive
Sagimet Biosciences	Neutral

Molecular Partners presently has a consensus target price of $8.38, indicating a potential upside of 96.37%. Sagimet Biosciences has a consensus target price of $29.17, indicating a potential upside of 167.83%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Sagimet Biosciences beats Molecular Partners on 12 of the 14 factors compared between the two stocks.

How does Molecular Partners compare to Crescent Biopharma?

Molecular Partners (NASDAQ:MOLN) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Molecular Partners has higher earnings, but lower revenue than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	N/A	N/A	-$74.41M	-$1.71	N/A
Crescent Biopharma	$10.84M	72.45	-$153.94M	-$6.72	N/A

Molecular Partners presently has a consensus target price of $8.38, suggesting a potential upside of 96.37%. Crescent Biopharma has a consensus target price of $29.60, suggesting a potential upside of 39.99%. Given Molecular Partners' higher probable upside, analysts plainly believe Molecular Partners is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Crescent Biopharma had 6 more articles in the media than Molecular Partners. MarketBeat recorded 6 mentions for Crescent Biopharma and 0 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.15 beat Crescent Biopharma's score of 0.17 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Molecular Partners	Positive
Crescent Biopharma	Neutral

Molecular Partners has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

26.5% of Molecular Partners shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Molecular Partners' return on equity of -68.36% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-68.36%	-54.82%
Crescent Biopharma	N/A	-101.50%	-86.86%

Summary

Molecular Partners and Crescent Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOLN vs. The Competition

Export

Metric	Molecular Partners	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$172.20M	$4.02B	$7.26B	$12.91B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-2.49	12.64	273.83	25.42
Price / Sales	N/A	1,362.02	676.21	123.96
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	2.33	16.28	12.89	6.17
Net Income	-$74.41M	-$22.72M	$3.48B	$349.24M
7 Day Performance	-7.50%	-1.62%	-0.36%	-1.42%
1 Month Performance	2.03%	10.88%	6.49%	2.53%
1 Year Performance	14.47%	53.32%	25.06%	15.84%

Molecular Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOLN Molecular Partners	3.0817 of 5 stars	$4.30 +5.6%	$8.38 +94.9%	+10.3%	$173.53M	N/A	N/A	180	Gap Up
IRWD Ironwood Pharmaceuticals	2.7913 of 5 stars	$4.29 -2.3%	$6.23 +45.3%	+236.6%	$708.88M	$389.32M	5.57	220	Positive News Analyst Revision
ALLO Allogene Therapeutics	2.2319 of 5 stars	$2.04 -6.0%	$8.30 +306.9%	+76.8%	$704.80M	$20K	N/A	310	News Coverage
TECX Tectonic Therapeutic	3.0979 of 5 stars	$35.97 -4.6%	$77.80 +116.3%	+82.5%	$703.21M	N/A	N/A	120	News Coverage Positive News Analyst Forecast
SGMT Sagimet Biosciences	3.1744 of 5 stars	$10.86 +5.5%	$29.17 +168.6%	+49.3%	$675.06M	$2M	N/A	8	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOLN) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Molecular Partners (MOLN) Competitors

MOLN vs. IRWD, ALLO, TECX, SGMT, and CBIO

How does Molecular Partners compare to Ironwood Pharmaceuticals?

Summary

How does Molecular Partners compare to Allogene Therapeutics?

Summary

How does Molecular Partners compare to Tectonic Therapeutic?

Summary

How does Molecular Partners compare to Sagimet Biosciences?

Summary

How does Molecular Partners compare to Crescent Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Molecular Partners (MOLN) Competitors

MOLN vs. IRWD, ALLO, TECX, SGMT, and CBIO

How does Molecular Partners compare to Ironwood Pharmaceuticals?

Is IRWD or MOLN more profitable?

Which has higher valuation & earnings, IRWD or MOLN?

Which has more risk and volatility, IRWD or MOLN?

Do analysts prefer IRWD or MOLN?

Do institutionals & insiders hold more shares of IRWD or MOLN?

Does the media prefer IRWD or MOLN?

Summary

How does Molecular Partners compare to Allogene Therapeutics?

Which has better earnings and valuation, ALLO or MOLN?

Which has more volatility and risk, ALLO or MOLN?

Is ALLO or MOLN more profitable?

Do analysts prefer ALLO or MOLN?

Does the media refer more to ALLO or MOLN?

Do institutionals and insiders hold more shares of ALLO or MOLN?

Summary

How does Molecular Partners compare to Tectonic Therapeutic?

Which has preferable earnings and valuation, TECX or MOLN?

Is TECX or MOLN more profitable?

Do institutionals & insiders believe in TECX or MOLN?

Does the media refer more to TECX or MOLN?

Which has more volatility & risk, TECX or MOLN?

Do analysts rate TECX or MOLN?

Summary

How does Molecular Partners compare to Sagimet Biosciences?

Is MOLN or SGMT more profitable?

Which has more volatility and risk, MOLN or SGMT?

Do institutionals and insiders believe in MOLN or SGMT?

Which has preferable earnings and valuation, MOLN or SGMT?

Does the media prefer MOLN or SGMT?

Do analysts rate MOLN or SGMT?

Summary

How does Molecular Partners compare to Crescent Biopharma?

Which has better earnings & valuation, MOLN or CBIO?

Do analysts rate MOLN or CBIO?

Does the media favor MOLN or CBIO?

Which has more risk & volatility, MOLN or CBIO?

Do institutionals and insiders believe in MOLN or CBIO?

Is MOLN or CBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools